专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015191179A1 TTP INHIBITIORS OF LOW DENSITY LIPPROTEIN SECRETION FOR THE MANAGEMENT OF DISEASES ASSOCIATED WITH ELEVATED BLOOD LDL LEVELS 审中-公开
标题翻译：低浓度LIPPROTEIN分泌的TTP抑制剂与高脂血症LDL水平相关的疾病管理
公开(公告)号：WO2015191179A1
公开(公告)日：2015-12-17
申请号：PCT/US2015/028730
申请日：2015-05-01
申请人： BARUCH S. BLUMBERG INSTITUTE
发明人： CUCONATI, Andrea , BLOCK, Timothy, M.
IPC分类号： A61K31/70 , C07D239/70
CPC分类号： A61K31/519
摘要： The present invention provides for the novel method for the inhibition of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formulas I-XI in lowering serum lipids and in the prevention and treatment of related disease. Regulation of the VLDL/LDL pathway as a therapeutic means to reduce hyperlipidemia is supported from studies in liver cells and in an animal model. Accordingly, the inhibition of regulation described herein is identified as a new therapeutic target for treatment of cardiovascular disease or diseases associated with cardiovascular disease such as hyperlipidemia. Treatment of cardiovascular disease and associated conditions or diseases with the novel TTP inhibitors of the invention reduces MTP protein associated lipid production without side effects that occur with other methods of MTP protein associated lipid inhibition. We describe small molecules (disubstituted tetrahydro-tetrazolo(l,5a)pyrimidine (TTP) and a method of their use to inhibit the secretion of ApoB and LDLs from liver derived cells in tissue culture and in animal models. We further describe how to use these small molecules in the management of diseases associated with elevations of circulating LDLs.
摘要翻译：本发明提供了抑制具有式I-XI的微粒体甘油三酯转移蛋白（MTP）和/或载脂蛋白B（Apo B）分泌物在降低血清脂质中的预防和治疗相关疾病的新方法。 VLDL / LDL途径的调节作为减少高脂血症的治疗手段得益于肝细胞和动物模型的研究。因此，本文所述的调节抑制被鉴定为用于治疗与心血管疾病如高脂血症相关的心血管疾病或疾病的新治疗靶标。使用本发明的新型TTP抑制剂治疗心血管疾病和相关病症或疾病可减少MTP蛋白相关的脂质生成，而不伴随MTP蛋白相关脂质抑制的其他方法发生副作用。我们描述了小分子（二取代四氢 - 四唑（1,5）嘧啶（TTP））及其在组织培养和动物模型中用于抑制来自肝源细胞的ApoB和LDL分泌的方法，我们进一步描述如何使用这些小分子治疗与循环低密度脂蛋白升高相关的疾病。

2. 发明申请

WO2010091304A1 A FILTER METHOD FOR SEPARATING FERROFLUIDS IN A BIOLOGICAL SAMPLE 审中-公开
标题翻译：用于分离生物样品中的流感的过滤方法
公开(公告)号：WO2010091304A1
公开(公告)日：2010-08-12
申请号：PCT/US2010/023388
申请日：2010-02-05
申请人： VERIDEX, LLC , TIBBE, Arjan, G.J.
发明人： TIBBE, Arjan, G.J.
IPC分类号： G01N33/543 , G01N33/553
CPC分类号： G01N33/54333
摘要： A filtering system for separating unbound ferrofluid from bound ferrofluid In the enrichment of a target entity in a biological sample. The filtering device of the present invention has application in the isolation target cells from unbound ferrofluid during separation with a permanent magnet (floater) mechanism. This process reduces Interference of unbound ferrofluid during subsequent image analysis or enumeration of cells by image cytometry. The system has application In the assessment of target populations such as leukocyte subsets In different bodily fluids or bacterial contamination in environmental samples, food products anύ bodily fluids. Briefly, fluorescently labeled target cells are linked to magnetic particles or beads. The linkage process results in a mixture having a population of contaminating unbound magnetic particles. In one embodiment for separation, a small, permanent magnet is inserted directly into the chamber containing the labeled cells. The.magnets are coated with PDMS Silicone rubber to provide a smooth and even surface which allows imaging on a single focal plane. A filter is positioned on a cover of the floater device to allow unbound ferrofluid to pass through the pores, but restrict the passage of the target entity. The floater and filter are removed from the sample and the filter surface is illuminated with fluorescent light emitted by the target cells captured by a CCD camera. Image analysis can be performed with a novel algorithm to provide a count of the cells on the surface, reflecting the target cell concentration of the original sample.
摘要翻译：将未结合的铁磁流体与结合的铁磁流体分离的过滤系统在生物样品中的目标实体的富集中。本发明的过滤装置在用永久磁铁（浮子）机构分离的同时，可以将其从未结合的铁磁流体中分离出来。该过程减少了随后的图像分析期间未结合的铁磁流体的干扰或通过图像细胞计数对细胞的计数。该系统已应用于评估目标人群如白细胞亚群在不同的体液或细菌污染的环境样本中，食品是？体液。简言之，荧光标记的靶细胞与磁性颗粒或珠子相连。连接过程产生具有污染的未结合磁性颗粒群的混合物。在用于分离的一个实施例中，将小的永磁体直接插入到含有标记细胞的腔室中。电磁铁用PDMS硅橡胶涂覆以提供光滑均匀的表面，允许在单个焦平面上成像。过滤器定位在浮子装置的盖上，以允许未结合的铁磁流体穿过孔，但限制目标实体的通过。从样品中除去浮子和过滤器，并用由CCD照相机捕获的靶细胞发射的荧光照射滤光片表面。可以用新颖的算法进行图像分析，以提供表面上的细胞计数，反映原始样品的靶细胞浓度。

3. 发明申请

WO2009132231A8 PEPTIDYL DIACYLGLYCERIDES 审中-公开
公开(公告)号：WO2009132231A8
公开(公告)日：2009-10-29
申请号：PCT/US2009/041595
申请日：2009-04-24
申请人： THERIMUNEX PHARMACEUTICALS, INC. , THACKER, James, D.
发明人： THACKER, James, D.
IPC分类号： A61K38/10
摘要： Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.

4. 发明申请

WO2009132231A2 PEPTIDYL DIACYLGLYCERIDES 审中-公开
公开(公告)号：WO2009132231A2
公开(公告)日：2009-10-29
申请号：PCT/US2009/041595
申请日：2009-04-24
申请人： THERIMUNEX PHARMACEUTICALS, INC. , THACKER, James, D.
发明人： THACKER, James, D.
IPC分类号： A61K38/10
CPC分类号： A61K38/10
摘要： Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.
摘要翻译：可以与脂质共价连接的肽和肽以及使用这些肽和脂肽预防或治疗疾病的方法在本文中公开。

5. 发明申请

WO2020051566A1 VACCINES WITH ENHANCED IMMUNE RESPONSE AND METHODS FOR THEIR PREPARATION 审中-公开
公开(公告)号：WO2020051566A1
公开(公告)日：2020-03-12
申请号：PCT/US2019/050116
申请日：2019-09-07
申请人： IMMUNOTOPE, INC. , PHILIP, Ramila
发明人： PHILIP, Ramila
IPC分类号： A61K38/00 , C07K1/107 , C07K2/00 , G01N33/50 , G01N33/53 , G01N33/569
摘要： Although numerous investigations are focused on developing vaccines that induce protective humoral responses, fewer studies are aimed at developing vaccines that induce broad and robust T cell responses. In order to design a potent T cell based vaccine, two critical components are needed: the identity of specific T cell epitopes and an optimized vaccine formulation capable of delivering the antigens and the adjuvants simultaneously. Previously, we have identified and characterized HLA-A2 and A24 binding conserved epitopes and have characterized the feasibility of epitope based vaccine for dengue infection. Using these T cell epitopes and N acetyl glucosamine incorporated into a calcium phosphate nanoparticle (CaPNP) delivery system as the model, we studied efficacy of such CTL vaccine. The present disclosure describes such a CTL vaccine utilizing such combination.. Evaluating the immunogenicity of CaPNP/Dengue peptides formulation in-vitro and in-vivo in HLA-transgenic mice demonstrates that the CaPNP vaccine is immunologically relevant to induce T cellresponses against all four serotypes of dengue virus infection. This formulation is simple, has a low investment manufacturing process, and is stable at room temperature in a lyophilized form, further reducing the manufacturing time and costs. Further, the formulation is a candidate for the development of effective multi-serotype specific dengue virus vaccine to be used as prophylactic vaccine to prevent dengue infection in non-infected healthy individuals, and has the potential to be used as a therapeutic vaccine in already infected individuals, to minimize the antibody mediated complications caused by secondary infections.

6. 发明申请

WO2019236953A1 A PANOPTES DEVICE OR IMAGE ACQUISITION SYSTEM HAVING MULTIPLE INDEPENDENT SENSORS 审中-公开
公开(公告)号：WO2019236953A1
公开(公告)日：2019-12-12
申请号：PCT/US2019/035969
申请日：2019-06-07
申请人： STOREVISION NORTH AMERICA INC.
发明人： KATZ, Barry
IPC分类号： G02B21/36 , H04N5/222 , H04N5/335 , H04N5/341
摘要： An acquisition imaging system is described herein that acquires multiple images from multiple imagers where each are sent to a single processor/controller, resulting in a single, resultant image providing a detailed field of view. The system is comprised of multiple sets of images taken by multiple sensors, strategically placed to acquire multiple perspectives of an image field. Each sensor is packaged with digitization, compression and communication components in an imager to allow for the transfer of the image to a processor/controller system controller. The system's controller acts as the network interface, power supply and centralized management for processing information, specifically the analytics. The present invention has applications in surveillance, event classification systems, indexed archival storage, real-time and post facto image content analytics, future filtering vectors; ad hoc querying, automatic queries, and multiple query languages.

7. 发明申请

WO2018236957A1 METHOD AND COMPOSITIONS FOR TREATING RESTLESS LEGS SYNDROME 审中-公开
公开(公告)号：WO2018236957A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038430
申请日：2018-06-20
申请人： NEXIEN BIOPHARMA, INC.
发明人： FRIEDLAND, Jeffrey , KLUMPERS, Linda
IPC分类号： A61K31/352 , A61K31/01 , A61P43/00 , A61P25/00
CPC分类号： A61P25/00 , A61K31/015 , A61K31/045 , A61K31/05 , A61K31/22 , A61K31/352 , A61P43/00 , A61K2300/00
摘要： Methods and compositions for treating restless legs syndrome.

8. 发明申请

WO2018071581A1 AN ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHODS OF USE THEREOF 审中-公开
标题翻译：提取大胡椒素的口服组合物及其使用方法
公开(公告)号：WO2018071581A1
公开(公告)日：2018-04-19
申请号：PCT/US2017/056201
申请日：2017-10-11
申请人： COLUMBIA CARE, LLC
发明人： DELY, Aaron
IPC分类号： A61K9/16 , A61K9/48 , A61K31/352
摘要： The present invention provides oral pharmaceutical compositions comprising the release of at least two cannabinoids in the treatment of disorders or the symptoms thereof. A method of manufacture for their preparation and methods of use thereof are also provided.
摘要翻译：本发明提供了口服药物组合物，其包含释放至少两种大麻素以治疗障碍或其症状。还提供了它们的制备方法及其使用方法。

9. 发明申请

WO2009123667A2 METHODS AND COMPOSITIONS INCLUDING DIAGNOSTIC KITS FOR THE DETECTION IN SAMPLES OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 审中-公开
标题翻译：含有耐甲氧西林黄曲霉毒素样品检测的诊断试剂盒的方法和组合物
公开(公告)号：WO2009123667A2
公开(公告)日：2009-10-08
申请号：PCT/US2008/088356
申请日：2008-12-26
申请人： ZEUS SCIENTIFIC, INC. , O'HARA, Shawn, Mark
发明人： O'HARA, Shawn, Mark
IPC分类号： C12Q1/68
CPC分类号： C12Q1/689
摘要： The present invention provides methods, compositions and diagnostic kits for the detection of Staphylococcus Aureus (SA) and antibiotic resistant forms and variants thereof, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin- resistant Staphylococcus aureus (VRSA), mupirocin- resistant Staphylococcus aureus (mupSA), and the like, in a sample population. The invention preferably involves the improvements of bacterial sampling by means of SA enrichment, followed by SA cell disruption and amplification procedures incorporating the use of multiplex assays for SA specific genes, such as mecA and coagulase negative Staphylococci (CONS) specific genes such as tufA, for SA identification and identification of its known species. This provides means for controlling for the thirty or more known CONS species in assessing SA samples, especially those CONS species that may carry antibiotic resistance genes, such as SCCmec.
摘要翻译：本发明提供用于检测金黄色葡萄球菌（SA）和抗生素抗性形式及其变体的方法，组合物和诊断试剂盒，例如耐甲氧西林金黄色葡萄球菌（MRSA），耐万古霉素金黄色葡萄球菌（VRSA），莫匹罗星耐药性样本群体中的金黄色葡萄球菌（mupSA）等。本发明优选地涉及通过SA富集来改进细菌取样，随后是SA细胞破碎和扩增程序，其包括使用针对SA特异性基因的多重测定法，例如mecA和凝固酶阴性葡萄球菌（CONS）特异性基因，例如tufA，用于SA识别和鉴定其已知物种。这提供了在评估SA样品，特别是可携带抗生素抗性基因的那些CONS物种（例如SCCmec）时，控制三十种以上已知的CONS物质的手段。

10. 发明申请

WO2020077322A1 NOVEL METHOD AND COMPOUNDS FOR TREATMENT OF COGNITIVE LOSS ASSOCIATED WITH ADULT ONSET LEUKODYSTROPHY WITH AXONAL SPHEROIDS AND PIGMENTED GLIA (ALSP) AND OTHER NEURODEGENERATIVE DISEASES INVOLVING REDUCED COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) SIGNALING 审中-公开
公开(公告)号：WO2020077322A1
公开(公告)日：2020-04-16
申请号：PCT/US2019/056019
申请日：2019-10-13
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
发明人： STANLEY, Richard E. , CHLITU, Violeta
IPC分类号： A61K39/395 , A61K38/18 , A61K39/00 , A61P25/28 , C07K14/475
摘要： Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is caused by dominant inactivating mutations in the colony stimulating factor receptor 1 (CSF1R) kinase domain. GM-CSF haploinsufficiency corrects olfactory, cognitive and emotional functions lost in Csflr+/- mice. This correlates with the correction of microgliosis and microglial functions resulting in improvement of myelination and rescue of neurogenesis. However, GM-CSF haploinsufficiency fails to correct the motor deficits of Csflr+/- mice and cerebellar microgliosis. The present invention discloses methods and compositions using GM-CSF as a suitable therapeutic target to inhibit in amelioration of the cognitive impairments in ALSP and other in conditions involving inflammatory activation of microglia and macrophages, such as AD, ALS, multiple sclerosis, and hippocampal inflammation following radiation therapy. Treatment with GM-CSF inhibitors is beneficial in ALSP, as adult neurogenesis is important for memory, olfaction and prevention of anxiety/depression and early initiation of such treatment in carriers of CSF1R mutations may increase effectiveness. Balancing the actions of CSF-1R and GM- CSF signaling are necessary to preserve olfaction, cognition and emotional balance in aged mice. This balance is likely altered in many neurodegenerative diseases in which activated microglia contribute to the pathology.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式